<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37422901</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>TBK1 variants in Chinese patients with amyotrophic lateral sclerosis: Genetic analysis and clinical features.</ArticleTitle><Pagination><StartPage>3079</StartPage><EndPage>3089</EndPage><MedlinePgn>3079-3089</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15973</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Haploinsufficiency of TANK-binding kinase 1 (TBK1) loss-of-function (LoF) variants has been shown to be pathogenic in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). However, the genetic spectrum of TBK1 and clinical features of ALS patients with TBK1 variants remain largely unknown in Asians.</AbstractText><AbstractText Label="METHODS">Genetic analysis was performed on 2011 Chinese ALS patients. Software was used to predict the deleteriousness of missense variants in TBK1. In addition, PubMed, Embase and Web of Science were searched for related literature.</AbstractText><AbstractText Label="RESULTS">Twenty-six TBK1 variants were identified in 33 of 2011 ALS patients, including six novel LoF variants (0.3%) and 20 rare missense variants, 12 of which were predicted to be deleterious (0.6%). In addition to TBK1 variants, 11 patients had other ALS-related gene variants. Forty-two previous studies found that the frequency of TBK1 variants was 1.81% in ALS/FTD patients. The frequency of TBK1 LoF variants in ALS was 0.5% (Asians 0.4%; Caucasian 0.6%) and that of missense variants was 0.8% (Asians 1.0%; Caucasian 0.8%). ALS patients with TBK1 LoF variants affecting the kinase domain had a significantly younger age of onset than patients carrying LoF variants affecting the coiled coil domains CCD1 and CCD2. FTD has a frequency of 10% in Caucasian ALS patients with TBK1 LoF variants, which was not found in our cohort.</AbstractText><AbstractText Label="CONCLUSION">Our study expanded the genotypic spectrum of ALS patients with TBK1 variants and found that the clinical manifestations of TBK1 carriers are diverse.</AbstractText><CopyrightInformation>&#xa9; 2023 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Bi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qirui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Junyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yanbing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Ruwei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kuncheng</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2671-2201</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tianmi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0947-1151</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TBK1 variant</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">genotype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>9</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>9</Day><Hour>14</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37422901</ArticleId><ArticleId IdType="doi">10.1111/ene.15973</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chou SM, Norris FH. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve. 1993;16(8):864-869. doi:10.1002/mus.880160810</Citation></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93(11):1617-1628. doi:10.1016/j.mayocp.2018.04.007</Citation></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471</Citation></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182-1194. doi:10.1016/s1474-4422(16)30199-5</Citation></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436-1441. doi:10.1126/science.aaa3650</Citation></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631-636. doi:10.1038/nn.4000</Citation></Reference><Reference><Citation>Le Ber I, De Septenville A, Millecamps S, et al. TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging. 2015;36(11):3116.e5-3116.e8. doi:10.1016/j.neurobiolaging.2015.08.009</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299. doi:10.1080/146608200300079536</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1-2):13-21. doi:10.1016/s0022-510x(99)00210-5</Citation></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179</Citation></Reference><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621-1626. doi:10.1212/wnl.55.11.1621</Citation></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x</Citation></Reference><Reference><Citation>Chong MS, Lim WS, Chan SP, et al. Diagnostic performance of the Chinese frontal assessment battery in early cognitive impairment in an Asian population. Dement Geriatr Cogn Disord. 2010;30(6):525-532. doi:10.1159/000321665</Citation></Reference><Reference><Citation>Lu J, Li D, Li F, et al. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. J Geriatr Psychiatry Neurol. 2011;24(4):184-190. doi:10.1177/0891988711422528</Citation></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.1136/jnnp.23.1.56</Citation></Reference><Reference><Citation>Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1111/j.2044-8341.1959.tb00467.x</Citation></Reference><Reference><Citation>Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med. 1972;52(6):81-85. doi:10.1080/00325481.1972.11713319</Citation></Reference><Reference><Citation>Chen Y, Lin Z, Chen X, et al. Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2016;38:217.e15-217.e22. doi:10.1016/j.neurobiolaging.2015.11.016</Citation></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30</Citation></Reference><Reference><Citation>Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886-D894. doi:10.1093/nar/gky1016</Citation></Reference><Reference><Citation>Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(2):62-73. doi:10.1080/14660820310011700</Citation></Reference><Reference><Citation>Arshad F, Vengalil S, Nalini A, et al. Novel TBK1 variant associated with frontotemporal dementia overlap syndrome. Acta Neurol Scand. 2022;145(4):399-406. doi:10.1111/ane.135620</Citation></Reference><Reference><Citation>Behler A, Knehr A, Finsel J, et al. Eye movement alterations in presymptomatic C9orf72 expansion gene carriers. J Neurol. 2021;268(9):3390-3399. doi:10.1007/s00415-021-10510-z</Citation></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:178.e11-178.e20. doi:10.1016/j.neurobiolaging.2016.12.013</Citation></Reference><Reference><Citation>Brenner D, M&#xfc;ller K, Lattante S, et al. FUS mutations dominate TBK1 mutations in FUS/TBK1 double-mutant ALS/FTD pedigrees. Neurogenetics. 2022;23(1):59-65. doi:10.1007/s10048-021-00671-4</Citation></Reference><Reference><Citation>Corcia P, Lunetta C, Couratier P, et al. Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: supplementary evidence for a continuum. Eur J Neurol. 2021;28(8):2780-2783. doi:10.1111/ene.14960</Citation></Reference><Reference><Citation>Costa MR, Gromicho M, Pronto-Laborinho AC, Miltenyi MG, de Carvalho M. Novel TBK1 LoF variant in a family with upper motor neuron predominant motor neuron disease. J Neurol Sci. 2019;403:117-118. doi:10.1016/j.jns.2019.06.029</Citation></Reference><Reference><Citation>de Majo M, Topp SD, Smith BN, et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol Aging. 2018;71:266.e1-266.e10. doi:10.1016/j.neurobiolaging.2018.06.015</Citation></Reference><Reference><Citation>Dols-Icardo O, Garc&#xed;a-Redondo A, Rojas-Garc&#xed;a R, et al. Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. J Neurol Neurosurg Psychiatry. 2018;89(2):162-168. doi:10.1136/jnnp-2017-316820</Citation></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85(24):2116-2125. doi:10.1212/wnl.0000000000002220</Citation></Reference><Reference><Citation>Gondim FAA, Fernandes JMA, Marques JW. ALS due to a novel TBK1 mutation in Brazil. Amyotroph Lateral Scler Frontotemporal Degener. 2022;4:1-3. doi:10.1080/21678421.2022.2028169</Citation></Reference><Reference><Citation>Gratten J, Zhao Q, Benyamin B, et al. Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese. Genome Med. 2017;9(1):97. doi:10.1186/s13073-017-0487-0</Citation></Reference><Reference><Citation>Hirsch-Reinshagen V, Alfaify OA, Hsiung G-YR, et al. Clinicopathologic correlations in a family with a TBK1 mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degener. 2019;20(7-8):568-575. doi:10.1080/21678421.2019.1632347</Citation></Reference><Reference><Citation>Jiao B, Sun Q, Yuan Z, et al. Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort. Transl Neurodegener. 2018;7:31. doi:10.1186/s40035-018-0136-6</Citation></Reference><Reference><Citation>Khoshnood B, Ullgren A, Laffita-Mesa J, et al. TBK1 haploinsufficiency results in changes in the K63-ubiquitination profiles in brain and fibroblasts from affected and presymptomatic mutation carriers. J Neurol. 2022;269(6):3037-3049. doi:10.1007/s00415-021-10887-x</Citation></Reference><Reference><Citation>Kim YE, Oh KW, Noh MY, et al. Genetic and functional analysis of TBK1 variants in Korean patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2017;50:170.e1-170.e6. doi:10.1016/j.neurobiolaging.2016.11.003</Citation></Reference><Reference><Citation>Koriath CA, Bocchetta M, Brotherhood E, et al. The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: a longitudinal case report. Alzheimers Dement (Amst). 2017;6:75-81. doi:10.1016/j.dadm.2016.10.003</Citation></Reference><Reference><Citation>Kotan D, &#xd6;z&#xf6;zen Ayas Z, Tunca C, Gungen BD, Ak&#xe7;imen F, Ba&#x15f;ak AN. Phenotypic and genotypic features of patients diagnosed with ALS in the city of Sakarya, Turkey. Acta Neurol Belg. 2020;120(6):1411-1418. doi:10.1007/s13760-020-01441-z</Citation></Reference><Reference><Citation>Lattante S, Doronzio PN, Marangi G, et al. Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging. 2019;84:239.e9-239.e14. doi:10.1016/j.neurobiolaging.2019.03.010</Citation></Reference><Reference><Citation>Libonati L, Ceccanti M, Cambieri C, et al. A novel homozygous mutation in TBK1 gene causing ALS-FTD. Neurol Sci. 2022;43(3):2101-2104. doi:10.1007/s10072-021-05820-z</Citation></Reference><Reference><Citation>Liu X, He J, Chen L, et al. TBK1 variants in Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2021;97:149.e9-149.e15. doi:10.1016/j.neurobiolaging.2020.07.028</Citation></Reference><Reference><Citation>Lu YQ, Chen JM, Lin H, et al. Novel intronic mutations of TBK1 promote aberrant splicing modes in amyotrophic lateral sclerosis. Front Mol Neurosci. 2022;15:691534. doi:10.3389/fnmol.2022.691534</Citation></Reference><Reference><Citation>Magnavita N, Sabatelli M, Scoditti E, Chirico F. Personalized prevention in mercury-induced amyotrophic lateral sclerosis: a case report. App Sci-Basel. 2020;10(21):7839. doi:10.3390/app10217839</Citation></Reference><Reference><Citation>McCann EP, Williams KL, Fifita JA, et al. The genotype&#x2212;phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92(3):259-266. doi:10.1111/cge.12973</Citation></Reference><Reference><Citation>McCombe PA, Ngo ST, Guo CC, et al. Patient with ALS with a novel TBK1 mutation, widespread brain involvement, behaviour changes and metabolic dysfunction. J Neurol Neurosurg Psychiatry. 2019;90(8):952-954. doi:10.1136/jnnp-2018-318823</Citation></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry. 2018;89(8):817-827. doi:10.1136/jnnp-2017-317611</Citation></Reference><Reference><Citation>Naruse H, Ishiura H, Mitsui J, et al. Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiol Aging. 2018;61:255.e9-255.e16. doi:10.1016/j.neurobiolaging.2017.08.030</Citation></Reference><Reference><Citation>Olsen CG, Busk &#xd8;L, Aanjesen TN, et al. Genetic epidemiology of amyotrophic lateral sclerosis in Norway-a 2-year population based study. Neuroepidemiology. 2022;56:271-282. doi:10.1159/000525091</Citation></Reference><Reference><Citation>Piaceri I, Bessi V, Mat&#xe0; S, et al. Association of the new variant Tyr424Asp at TBK1 gene with amyotrophic lateral sclerosis and cognitive decline. J Alzheimers Dis. 2018;61(1):41-46. doi:10.3233/jad-170694</Citation></Reference><Reference><Citation>Pozzi L, Valenza F, Mosca L, et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J Neurol Neurosurg Psychiatry. 2017;88(10):869-875. doi:10.1136/jnnp-2017-316174</Citation></Reference><Reference><Citation>Sch&#xf6;necker S, Brendel M, van der Zee J, et al. [A Pair of Siblings with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis and a Novel Thr462Lysfs Mutation in the TBK1 Gene]. Fortschr Neurol Psychiatr. 2016;84(8):494-498. doi:10.1055/s-0042-110653</Citation></Reference><Reference><Citation>Seibert K, Smith H, Lapins A, Pytel P, Mastrianni JA. A novel TBK1 variant (Lys694del) presenting with corticobasal syndrome in a family with FTD&#x2212;ALS spectrum diseases: case report. Front Neurol. 2022;13:826676. doi:10.3389/fneur.2022.826676</Citation></Reference><Reference><Citation>Shu S, Li XL, Liu Q, et al. Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7-8):605-607. doi:10.1080/21678421.2016.1183681</Citation></Reference><Reference><Citation>Swift IJ, Bocchetta M, Benotmane H, Woollacott IO, Shafei R, Rohrer JD. Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature. Neurobiol Aging. 2021;99:100.e9-100.e15. doi:10.1016/j.neurobiolaging.2020.08.014</Citation></Reference><Reference><Citation>Tohnai G, Nakamura R, Sone J, et al. Frequency and characteristics of the TBK1 gene variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2018;64:158.e15-158.e19. doi:10.1016/j.neurobiolaging.2017.12.005</Citation></Reference><Reference><Citation>Tripolszki K, Gampawar P, Schmidt H, et al. Comprehensive genetic analysis of a Hungarian amyotrophic lateral sclerosis cohort. Front Genet. 2019;10:732. doi:10.3389/fgene.2019.00732</Citation></Reference><Reference><Citation>Tsai PC, Liu YC, Lin KP, et al. Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2016;40:191.e11-191.e16. doi:10.1016/j.neurobiolaging.2015.12.022</Citation></Reference><Reference><Citation>van der Zee J, Gijselinck I, Van Mossevelde S, et al. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum Mutat. 2017;38(3):297-309. doi:10.1002/humu.23161</Citation></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139:452-467. doi:10.1093/brain/awv358</Citation></Reference><Reference><Citation>Weinreich M, Shepheard SR, Verber N, et al. Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2020;46(3):279-291. doi:10.1111/nan.12578</Citation></Reference><Reference><Citation>Williams KL, McCann EP, Fifita JA, et al. Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. Neurobiol Aging. 2015;36(12):3334.e1-3334.e5. doi:10.1016/j.neurobiolaging.2015.08.013</Citation></Reference><Reference><Citation>Wild P, Farhan H, McEwan DG, et al. Phosphorylation of the autophagy receptor optineurin restricts salmonella growth. Science. 2011;333(6039):228-233. doi:10.1126/science.1205405</Citation></Reference><Reference><Citation>Pilli M, Arko-Mensah J, Ponpuak M, et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity. 2012;37(2):223-234. doi:10.1016/j.immuni.2012.04.015</Citation></Reference><Reference><Citation>Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4(5):491-496. doi:10.1038/ni921</Citation></Reference><Reference><Citation>Helgason E, Phung QT, Dueber EC. Recent insights into the complexity of TANK-binding kinase 1 signaling networks: the emerging role of cellular localization in the activation and substrate specificity of TBK1. FEBS Lett. 2013;587(8):1230-1237. doi:10.1016/j.febslet.2013.01.059</Citation></Reference><Reference><Citation>Newman AC, Scholefield CL, Kemp AJ, et al. TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-&#x3ba;B signalling. PloS One. 2012;7(11):e50672. doi:10.1371/journal.pone.0050672</Citation></Reference><Reference><Citation>Ou YH, Torres M, Ram R, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell. 2011;41(4):458-470. doi:10.1016/j.molcel.2011.01.019</Citation></Reference><Reference><Citation>Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-112. doi:10.1038/nature08460</Citation></Reference><Reference><Citation>Cl&#xe9;ment JF, Meloche S, Servant MJ. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 2008;18(9):889-899. doi:10.1038/cr.2008.273</Citation></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223-226. doi:10.1038/nature08971</Citation></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68(11):1440-1446. doi:10.1001/archneurol.2011.250</Citation></Reference><Reference><Citation>Cui R, Tuo M, Li P, Zhou C. Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. Neurol Sci. 2018;39(5):811-820. doi:10.1007/s10072-018-3246-0</Citation></Reference><Reference><Citation>Foster AD, Downing P, Figredo E, et al. Correlates with the phosphorylation of TBK1 substrates. Mol Cell Neurosci. 2020;108:103539. doi:10.1016/j.mcn.2020.103539</Citation></Reference><Reference><Citation>Santos-Garcia D, Pozojevic J, de Deus FT, et al. First case of parkinsonian-pyramidal syndrome associated with a TBK1 mutation. Mov Disord. 2021;36(2):523-525. doi:10.1002/mds.28405</Citation></Reference><Reference><Citation>Seibert K, Smith H, Lapins A, Pytel P, Mastrianni J. Corticobasal syndrome associated with a novel Lys694del variant of the TBK1 gene. Alzheimers Dement. 2021;17(Suppl 3):e054756. doi:10.1002/alz.054756</Citation></Reference><Reference><Citation>Wilke C, Baets J, De Bleecker JL, et al. Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol Aging. 2018;62:244.e9-244.e13. doi:10.1016/j.neurobiolaging.2017.10.010</Citation></Reference><Reference><Citation>Eger SJ, Guen YL, Belloy ME, Napolioni V, Greicius MD. Rare TBK1 variant may confer protection in an APOE*4+ family. Alzheimers Dement. 2021;17(Suppl 3):e056632. doi:10.1002/alz.056632</Citation></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, et al. TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiol Aging. 2016;43:180.e1-5. doi:10.1016/j.neurobiolaging.2016.03.028</Citation></Reference><Reference><Citation>Bettencourt C, Houlden H. Exome sequencing uncovers hidden pathways in familial and sporadic ALS. Nat Neurosci. 2015;18(5):611-613. doi:10.1038/nn.4012</Citation></Reference><Reference><Citation>Zhang M, McKeever PM, Xi Z, et al. DNA methylation age acceleration is associated with ALS age of onset and survival. Acta Neuropathol. 2020;139(5):943-946. doi:10.1007/s00401-020-02131-z</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>